natgillin/translations-raw huggingface dataset:
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day).
Farmakokinetički/farmakodinamički (FK/FD) odnos između plazmatskih koncentracija rivaroksabana i nekoliko farmakodinamičkih ishoda (inhibicija faktora Xa, PV, APTV, Heptest) procjenjivan je nakon primjene širokog raspona doza (5 – 30 mg dvaput na dan).
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor-Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day).
Farmakokinetički/farmakodinamički (FK/FD) odnos između plazmatskih koncentracije rivaroksabana i nekoliko farmakodinamičkih ishoda (inhibicija faktora Xa, PV, APTV, Heptest) procjenjivan je nakon primjene širokog raspona doza (5- 30 mg dvaput na dan).
The pharmacokinetic/pharmacodynamic relationship in humans for IOP- lowering has not been established.
Farmakokinetički/farmakodinamički odnos kod ljudi pri sniženju IOT-a nije ustanovljen.
The pharmacokinetics (PK) of daratumumab following intravenous administration were evaluated in patients with relapsed and refractory multiple myeloma at dose levels from 0.1 mg/kg to 24 mg/kg.
Farmakokinetika daratumumaba nakon intravenske primjene ocjenjivala se u bolesnika s relapsnim i refraktornim multiplim mijelomom pri razinama doza od 0,1 mg/kg do 24 mg/kg.
The pharmacokinetics (PK) of nintedanib can be considered linear with respect to time (i.e. single- dose data can be extrapolated to multiple-dose data).
Farmakokinetika (PK) nintedaniba može se smatrati linearnom u odnosu na vrijeme (tj. podaci o jednokratnoj dozi mogu se ekstrapolirati na podatke o višekratnim dozama).
The pharmacokinetics and dosing
Farmakokinetika i preporuke za
The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by co- administration of mycophenolate mofetil (see also section 5.2).
Farmakokinetika i farmakodinamika oralnih kontraceptiva nije se izmijenila njihovom istodobnom primjenom s mofetilmikofenolatom (vidjeti i dio 5.2).
The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by co-administration of CellCept (see also section 5.2).
Farmakokinetika i farmakodinamika oralnih kontraceptiva nije se izmijenila njihovom istodobnom primjenom s lijekom CellCept (vidjeti i dio 5.2).
The pharmacokinetics and safety of a single loading dose of iv lacosamide were determined in a multicenter, open-label study designed to assess the safety and tolerability of rapid initiation of lacosamide using a single iv loading dose (including 200 mg) followed by twice daily oral dosing (equivalent to the iv dose) as adjunctive therapy in adult subjects 16 to 60 years of age with partial-onset seizures.
Farmakokinetika i sigurnost jednokratne udarne doze i.v. lakozamida utvrđena je u multicentričnom otvorenom ispitivanju dizajniranom za ocjenu sigurnosti i podnošljivosti brzog uvođenja lakozamida koristeći jednokratnu i.v. udarnu dozu (koja uključuje 200 mg) nakon koje slijedi oralno doziranje dvaput dnevno (ekvivalentno i.v. dozi) kao dodatna terapija u odraslih ispitanika u dobi od 16 do 60 godina s parcijalnim napadajima.
The pharmacokinetics and systemic exposure to amifampridine is notably influenced by the overall metabolic acetylation activity of the polymorphic N-acetyl-transferase (NAT) enzymes (acetylator phenotype) and NAT2 genotype, which is subject to genetic variation (see section 5.2), as shown in the healthy volunteer study.
Farmakokinetika i sistemska izloženost amifampridinu pod znatnim je utjecajem ukupne metaboličke acetilacijske aktivnosti polimorfnih enzima N-acetiltransferaza (NAT) (fenotip acetilatora), te genotipa NAT2 koji je podložan genetskim varijacijama (vidjeti dio 5.2) kako je to i prikazano u ispitivanju na zdravim dobrovoljcima.
The pharmacokinetics in paediatric subjects after multiple doses has not been studied.
Farmakokinetika nakon višestrukih doza nije ispitana u pedijatrijskoj populaciji.
The pharmacokinetics in patients below the age of 18 has not been studied.
Farmakokinetika u bolesnika mlađih od 18 godina nije ispitivana.
The pharmacokinetics in patients with renal or hepatic impairment has not been characterised.
Farmakokinetika u bolesnika s oštećenjem funkcije bubrega ili jetre nije opisana.
The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Farmakokinetika kod bolesnika s oštećenjem funkcije bubrega ili jetre nije opisana.
The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Farmakokinetika u bolesnika s oštećenjem jetrene ili bubrežne funkcije nije opisana.
The pharmacokinetics is not altered with repeat dosing.
Farmakokinetika se ne mijenja kod ponavljajućeg doziranja.
The pharmacokinetics of a 20 mg single dose of bazedoxifene were evaluated in a study in 26 healthy postmenopausal women.
Farmakokinetika jednokratne doze bazedoksifena od 20 mg ispitivana je u 26 zdravih postmenopauzalnih žena.
The pharmacokinetics of a single 4 mg dose of mifamurtide following a 1 hour intravenous infusion were evaluated in adult volunteers with mild (Child-Pugh class A; n=9) or moderate (Child-Pugh class B; n=8) hepatic impairment and in age- ,sex-, and weight-matched healthy adults with normal hepatic function (n=19).
Farmakokinetika jednostruke doze od 4 mg mifamurtida nakon jednosatne intravenske infuzije ispitana je u odraslih dobrovoljaca s blagim (Child-Pugh stadij A, n=9) ili umjerenim (Child-Pugh stadij B, n=8) oštećenjem jetre i u zdravih odraslih s normalnom jetrenom funkcijom (n=19) usklađenih po dobi, spolu i tjelesnoj težini.
The pharmacokinetics of a single 4mg dose of mifamurtide following a 1 hour intravenous infusion were evaluated in adult volunteers with mild (n=9) or moderate (n=8) renal impairment and in age- , sex-, and weight-matched healthy adults with normal renal function (n=16).
Farmakokinetika jednostruke doze od 4 mg mifamurtida nakon jednosatne intravenske infuzije ispitana je u odraslih dobrovoljaca s blagim (n=9) ili umjerenim (n=8) oštećenjem bubrega i u zdravih odraslih s normalnom bubrežnom funkcijom (n=16) usklađenih po dobi, spolu i tjelesnoj težini.
The pharmacokinetics of A771726 following oral administration of leflunomide have been investigated in 73 paediatric patients with polyarticular course Juvenile Rheumatoid Arthrit is (JRA) who ranged in age from 3 to 17 years.
Farmakokinetika A771726 nakon peroralne primjene leflunomida ispitivana je u 73 pedijatrijska bolesnika u dobi od 3 do 17 godina s poliartikuliranim oblikom juvenilnog reumatoidnog artritisa (JRA).
The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose; the median (range) AUC values was 24.1 (10.4 to 54.8) ug.h/ml.
Farmakokinetika abakavira ispitivana je u bolesnika s blagim oštećenjem jetre (Child-Pugh vrijednost 5-6) koji su primili jednokratnu dozu od 600 mg; medijan (raspon) AUC vrijednosti bio je 24,1 (10,4 do 54,8) ug.h/ml.
The pharmacokinetics of afamelanotide have not been fully characterised yet, i.e. distribution, metabolism or excretion are not clear.
Farmakokinetika afamelanotida još uvijek nije u potpunosti okarakterizirana, odnosno distribucija, metabolizam ili izlučivanje nisu jasni.
The pharmacokinetics of aliskiren are not significantly affected in patients with mild to moderate liver disease.
U bolesnika s blagom do umjerenom bolešću jetre nije bilo značajnog utjecaja na farmakokinetiku aliskirena i hidroklorotiazida.
The pharmacokinetics of alogliptin in children and adolescents < 18 years old has not been established.
Farmakokinetika alogliptina u djece i adolescenata < 18 godina starosti nije ispitana.
The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment; therefore, caution should be exercised when administering Rasilamlo to patients with hepatic impairment.
Farmakokinetika amlodipina nije ispitivana u bolesnika s teškim oštećenjem jetrene funkcije, stoga je nužan oprez kod primjene lijeka Rasilamlo bolesnicima s oštećenjem jetre.
The pharmacokinetics of apremilast and its major metabolite M12 are not affected by moderate or severe hepatic impairment.
Na farmakokinetiku apremilasta i njegova glavnog metabolita M12 ne utječe umjereno ili teško oštećenje funkcije jetre.
The pharmacokinetics of Atripla have not been studied in HIV infected patients with hepatic impairment.
Farmakokinetika Atriple nije ispitana u pacijenata inficiranih virusom HIV-a s oštećenjem funkcije jetre.
The pharmacokinetics of Atripla have not been studied in patients with hepatic impairment.
Farmakokinetika Atriple nije ispitana u pacijenata s oštećenjem funkcije jetre.
The pharmacokinetics of autoinduction is characterised by an approximately 1.5 to 2 fold increase in the apparent oral clearance of nevirapine as treatment continues from a single dose to two-to-four weeks of dosing with 200-400 mg/day.
Farmakokinetička autoindukcija karakterizirana je povećanjem prividnog oralnog klirensa nevirapina za 1,5-2 puta kako se liječenje nastavlja od jednokratne doze do doziranja od 200-400 mg/dan tijekom dva do četiri tjedna.
The pharmacokinetics of autoinduction is characterized by an approximately 1.5 to 2 fold increase in the apparent oral clearance of nevirapine as treatment continues from a single dose to two-to-four weeks of dosing with 200-400 mg/day.
Farmakokinetička autoindukcija karakterizirana je povećanjem vidljivog oralnog klirensa nevirapina za 1,5-2 puta kako se liječenje nastavlja od jednokratne doze do doziranja od 200-400 mg/dan tijekom dva do četiri tjedna.
The pharmacokinetics of avibactam in patients with any degree of hepatic impairment has not been studied.
Farmakokinetika avibaktama kod bolesnika s bilo kojim stupnjem oštećenja funkcije jetre nije ustanovljena.
The pharmacokinetics of azilsartan have not been studied in children under 18 years of age.
Farmakokinetika azilsartana nije ispitana u djece u dobi manjoj od 18 godina.
The pharmacokinetics of bazedoxifene have not been studied in the paediatric population.
Farmakokinetika bazedoksifena nije ispitivana u pedijatrijskoj populaciji.
The pharmacokinetics of blinatumomab appear linear over a dose range from 5 to 90 mcg/m2/day (approximately equivalent to 9-162 mcg/day) in adult patients.
Čini se da je farmakokinetika blinatumomaba linearna u rasponu doza od 5 do 90 µg/m2/dan (približno odgovara 9-162 µg/dan) u odraslih bolesnika.
The pharmacokinetics of bosentan have not been studied in patients with Child-Pugh class C hepatic impairment STAYVEER is contra-indicated in patients with moderate to severe hepatic impairment, i.e., Child-Pugh class B or C (see section 4.3).
Farmakokinetika bosentana nije ispitivana u bolesnika sa smanjenjem jetrene funkcije Child-Pugh stadij C. STAYVEER je kontraindiciran kod bolesnika s umjerenim do teškim oštećenjem jetre, npr., Child-Pugh stadij B ili C (vidjeti dio 4.3).
The pharmacokinetics of brivaracetam was not significantly affected by race (Caucasian, Asian) in a population pharmacokinetic modeling from epilepsy patients.
Populacijsko farmakokinetičko modeliranje provedeno u bolesnika s epilepsijom pokazalo je da rasa (bijela, azijska) nije značajno utjecala na farmakokinetiku brivaracetama.
The pharmacokinetics of CE/bazedoxifene have not been evaluated in patients with renal impairment.
Farmakokinetika KE/bazedoksifena nije ispitivana u bolesnica s oštećenom funkcijom bubrega.
The pharmacokinetics of CE/bazedoxifene have not been evaluated in women over 75 years of age.
Farmakokinetika KE/bazedoksifena nije ispitivana u žena starijih od 75 godina.
The pharmacokinetics of CE/bazedoxifene have not been evaluated in women with hepatic impairment.
Farmakokinetika KE/bazedoksifena nije ispitivana u žena s oštećenom funkcijom jetre.
The pharmacokinetics of ceftaroline in patients with hepatic impairment has not been established.
Nije utvrđena farmakokinetika ceftarolina u bolesnika s oštećenjem funkcije jetre.
The pharmacokinetics of ceftaroline was similar between males and females.
Farmakokinetika ceftarolina bila je podjednaka u muškaraca i žena.
The pharmacokinetics of ceftazidime in patients with severe hepatic impairment has not been established.
Farmakokinetika ceftazidima kod bolesnika s teškim oštećenjem funkcije jetre nije ustanovljena.
The pharmacokinetics of ceftazidime/avibactam is not significantly affected by gender or race.
Spol i rasa ne utječu značajno na farmakokinetiku ceftazidima/avibaktama.
The pharmacokinetics of ceritinib have not been studied in patients with moderate to severe hepatic impairment.
Farmakokinetika ceritiniba nije bila ispitivana u bolesnika s umjerenim do teškim oštećenjem jetre.
The pharmacokinetics of cinacalcet does not change over time.
Farmakokinetika sinakalceta s vremenom se ne mijenja.
The pharmacokinetics of cinacalcet have been studied in 12 paediatric patients (6-17 years) with CKD receiving dialysis following a single, oral, 15 mg dose.
Farmakokinetika sinakalceta ispitana je u 12 pedijatrijskih bolesnika (6 - 17 godina) s kroničnom bolesti bubrega koji su bili na dijalizi, nakon jedne oralne doze od 15 mg.
The pharmacokinetics of clofarabine were studied in 40 patients aged between 2 to 19 years old with relapsed or refractory ALL or AML.
Farmakokinetika klofarabina ispitana je u 40 bolesnika u dobi između 2 i 19 godina s relapsnom ili refraktornom ALL ili AML.
The pharmacokinetics of cobimetinib were evaluated in 6 subjects with mild hepatic impairment (Child Pugh A), 6 subjects with moderate hepatic impairment (Child Pugh B), 6 subjects with severe hepatic impairment (Child Pugh C) and 10 healthy subjects.
Farmakokinetika kobimetiniba ocjenjivala se u 6 ispitanika s blagim oštećenjem jetrene funkcije (Child-Pugh stadij A), 6 ispitanika s umjerenim oštećenjem jetrene funkcije (Child-Pugh stadij B), 6 ispitanika s teškim oštećenjem jetrene funkcije (Child-Pugh stadij C) i 10 zdravih ispitanika.
The pharmacokinetics of cysteamine bitartrate has not been studied in special populations.
Farmakokinetika cisteamin bitartrata nije se ispitivala na posebnim populacijama.
The pharmacokinetics of daclatasvir following a single 30 mg oral dose were studied in non-HCV infected subjects with mild (Child-Pugh A), moderate (Child-Pugh B), and severe (Child-Pugh C) hepatic impairment compared with unimpaired subjects.
Farmakokinetika daklatazvira nakon primjene jednokratne peroralne doze od 30 mg ispitivana je u bolesnika bez infekcije HCV-om s blagim (Child-Pugh A), umjerenim (Child-Pugh B) i teškim (Child-Pugh C) oštećenjem jetrene funkcije u usporedbi s ispitanicima sa zdravom jetrenom funkcijom.
The pharmacokinetics of daptomycin after a single 4 mg/kg dose of Cubicin were evaluated in three groups of paediatric patients with proven or suspected Gram-positive infection (2-6 years, 7-11 years and 12-17 years).
Farmakokinetika daptomicina nakon primjene jednokratne doze Cubicina od 4 mg/kg ispitivana je u tri dobne skupine pedijatrijskih bolesnika s dokazanom Gram-pozitivnom infekcijom ili sa sumnjom na nju (2-6 godina, 7-11 godina i 12-17 godina).
The pharmacokinetics of daptomycin appears to be linear in the dose range studied.
Čini se da je farmakokinetika daptomicina linearna u ispitivanom rasponu doza.
The pharmacokinetics of daptomycin following a single 4 mg/kg dose in adolescents aged 12-17 years are generally similar to those of healthy adult subjects with normal renal function with trends towards lower AUC and Cmax in adolescents.
Farmakokinetika daptomicina nakon jednokratne doze od 4 mg/kg u adolescenata u dobi od 12-17 godina općenito je bila slična onoj u zdravih odraslih ispitanika s urednom funkcijom bubrega, uz trend prema nižem AUC-u i Cmax u adolescenata.
The pharmacokinetics of darifenacin have not been established in the paediatric population.
Farmakokinetika darifenacina u pedijatrijskoj populaciji nije utvrđena.
The pharmacokinetics of decitabine following intravenous administration as a 1-hour infusion were described by a linear two-compartment model, characterised by rapid elimination of the drug from the central compartment and by relatively slow distribution from the peripheral compartment.
Farmakokinetika decitabina nakon intravenske primjene u obliku infuzije u trajanju od 1 sata bila je opisana kao linearni model s dva odjeljka, karakteriziran brzom eliminacijom lijeka iz središnjeg odjeljka i relativno sporom distribucijom iz perifernog odjeljka.
The pharmacokinetics of deferasirox have not been studied in elderly patients (aged 65 or older).
Farmakokinetika deferasiroksa nije ispitivana u starijih bolesnika (u dobi od 65 godina ili starijih).
The pharmacokinetics of dextromethorphan/quinidine in paediatric patients has not been studied (see section 5.1).
Farmakokinetika dekstrometorfana / kinidina u pedijatrijskih bolesnika nije ispitana (vidjeti dio 5.1).
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20- 115 mg/m2 in phase I studies.
Farmakokinetička svojstva docetaksela ispitivala su se u fazi I ispitivanja u bolesnika s karcinomom nakon primjene 20 - 115 mg/m2.
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20-115 mg/m2 in phase I studies.
Farmakokinetička svojstva docetaksela ispitivala su se u kliničkim ispitivanjim faze I u bolesnika s karcinomom nakon primjene 20 - 115 mg/m2.
The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents (12 to 17 years) showed that dolutegravir 50 mg once daily dosage resulted in dolutegravir exposure comparable to that observed in adults who received dolutegravir 50 mg once daily.
Farmakokinetika dolutegravira u 10 adolescenata (u dobi od 12 do 17 godina) s HIV-1 infekcijom, koji su prethodno liječeni antiretroviroticima, pokazala je da primjena dolutegravira u dozi od 50 mg jedanput na dan dovodi do izloženosti dolutegraviru usporedive s onom primijećenom u odraslih bolesnika koji su primali dolutegravir u dozi od 50 mg jedanput na dan.
The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents (12 to <18 years of age) showed that Tivicay 50 mg once daily oral dosage resulted in dolutegravir exposure comparable to that observed in adults who received Tivicay 50 mg orally once daily.
Farmakokinetika dolutegravira u 10 adolescenata (12 do < 18 godina) s HIV-1 infekcijom, koji su prethodno liječeni antiretroviroticima, pokazala je da peroralna primjena lijeka Tivicay u dozi od 50 mg jedanput na dan dovodi do izloženosti dolutegraviru usporedive s onom primijećenom u odraslih bolesnika koji su primali Tivicay u peroralnoj dozi od 50 mg jedanput na dan.
The pharmacokinetics of drugs that are mainly metabolised by UGT1A3 and UGT1A9 could be affected when administered concomitantly with ospemifene and co-administration should be made with caution.
Na farmakokinetiku lijekova koji se uglavnom metaboliziraju preko enzima UGT1A3 i UGT1A9 može se utjecati kada se daju istodobno s ospemifenom te je pri istodobnoj primjeni potreban oprez.
The pharmacokinetics of eculizumab was evaluated in Study M07-005 including 7 PNH paediatric patients (aged from 11 to less than 18 years).
Farmakokinetika ekulizumaba procijenjena je u ispitivanju M07-005 uključivši 7 pedijatrijskih bolesnika s PNH-om (u dobi od 11 do manje od 18 godina).
The pharmacokinetics of efavirenz have not been studied in patients with renal impairment.
Farmakokinetika efavirenza nije ispitana u pacijenata s oštećenjem funkcije bubrega.
The pharmacokinetics of efavirenz in paediatric patients were similar to adults.
Farmakokinetika efavirenza u djece bila je slična onoj u odraslih.
The pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil fumarate after co-administration of the separate pharmaceutical forms or as Atripla have not been studied in HIV infected patients with renal impairment.
Farmakokinetika efavirenza, emtricitabina i tenofovirdizoproksilfumarata nakon njihove istovremene primjene kao zasebnih farmaceutskih oblika ili davanja u obliku Atriple nije istraživana u pacijenata inficiranim virusom HIV-a s oštećenjem funkcije bubrega.
The pharmacokinetics of eltrombopag has been studied after administration of eltrombopag to adult subjects with hepatic impairment.
Farmakokinetika eltrombopaga proučavana je nakon primjene eltrombopaga odraslim osobama s jetrenim oštećenjem.
The pharmacokinetics of eltrombopag has been studied after administration of eltrombopag to adult subjects with renal impairment.
Farmakokinetika eltrombopaga proučavana je nakon primjene eltrombopaga odraslim osobama s bubrežnim oštećenjem.
The pharmacokinetics of eltrombopag have been evaluated in 168 paediatric ITP subjects dosed once daily in two studies, TRA108062/PETIT and TRA115450/PETIT-2.
Farmakokinetika eltrombopaga ocijenjena je u 168 pedijatrijskih ispitanika s ITP-om koji su primali dozu jednom dnevno u dva ispitivanja, TRA108062/PETIT i TRA115450/PETIT-2.
The pharmacokinetics of elvitegravir or cobicistat in paediatric subjects have not been fully established.
Farmakokinetika elvitegravira i kobicistata u pedijatrijskih ispitanika nije potpuno ustanovljena.
The pharmacokinetics of elvitegravir, cobicistat and tenofovir have been studied in patients with moderate hepatic impairment.
Farmakokinetika elvitegravira, kobicistata i tenofovira ispitana je u pacijenata s umjerenim oštećenjem funkcije jetre.
The pharmacokinetics of empagliflozin have been extensively characterised in healthy volunteers and patients with type 2 diabetes.
Farmakokinetika empagliflozina opsežno je ispitana u zdravih dobrovoljaca i bolesnika sa šećernom bolešću tipa 2.
The pharmacokinetics of empagliflozin have been extensively characterised in healthy volunteers and patients with type 2 diabetes.
Farmakokinetika empagliflozina opsežno je karakterizirana u zdravih dobrovoljaca i bolesnika sa šećernom bolešću tipa 2.
The pharmacokinetics of emtricitabine / tenofovir disoproxil have not been studied in subject with hepatic impairment.
Farmakokinetika emtricitabina/tenofovirdizoproksila nije ispitana u osoba s oštećenjem funkcije jetre.
The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co-infected with HBV and/or HCV.
Farmakokinetika emtricitabina i tenofoviralafenamida nije potpuno procijenjena u bolesnika koji su istodobno zaraţeni HBV-om i/ili HCV-om.
The pharmacokinetics of emtricitabine and tenofovir are altered in subjects with renal impairment.
Farmakokinetika emtricitabina i tenofovira izmijenjena je u ispitanika s oštećenjem funkcije bubrega.
The pharmacokinetics of emtricitabine and tenofovir are similar in male and female patients.
Farmakokinetike emtricitabina i tenofovira slične su u pacijenata muškog i ženskog spola.
The pharmacokinetics of emtricitabine has not been studied in patients with hepatic impairment.
Farmakokinetika emtricitabina nije ispitana u bolesnika s oštećenjem jetrene funkcije.
The pharmacokinetics of emtricitabine have not been studied in non-HBV infected patients with varying degrees of hepatic insufficiency.
Farmakokinetika emtricitabina nije ispitana u pacijenata koji nisu zaraženi virusom HBV-a, a koji imaju različiti stupanj hepatalne insuficijencije.
The pharmacokinetics of emtricitabine have not been studied in non-HBV infected subjects with varying degrees of hepatic insufficiency.
Farmakokinetika emtricitabina nije ispitana u ispitanika koji nisu zaraženi HBV-om, a imaju različit stupanj insuficijencije jetre.
The pharmacokinetics of emtricitabine have not been studied in patients with hepatic impairment.
Farmakokinetika emtricitabina nije ispitivana u pacijenata s oštećenjem funkcije jetre.
The pharmacokinetics of emtricitabine have not been studied in patients with hepatic impairment.
Farmakokinetika emtricitabina nije ispitivana u pacijenata s oštećenjem jetre.